

Genomic Characterisation of Invasive Non-Typhoidal *Salmonella enterica* Subspecies *enterica* Serovar Bovismorbificans Isolates from Malawi

Christina Bronowski^{1,9}, Maria C. Fookes^{2,9}, Ruth Gilderthorp², Kevin E. Ashelford³, Simon R. Harris², Amos Phiri⁴, Neil Hall³, Melita A. Gordon^{1,4,5}, John Wain⁶, Charles A. Hart¹, Paul Wigley¹, Nicholas R. Thomson^{2,1*}, Craig Winstanley^{1,†}

1 Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom, **2** Pathogen Genomics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom, **3** Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom, **4** Malawi-Liverpool-Wellcome Trust Clinical Research Program, Queen Elizabeth Hospital, Blantyre, Malawi, **5** Department of Medicine, College of Medicine, University of Malawi, Malawi, **6** Department of Medical Microbiology, University of East Anglia, Norwich Research Park, Norwich, United Kingdom

Abstract

Background: Invasive Non-typhoidal *Salmonella* (iNTS) are an important cause of bacteraemia in children and HIV-infected adults in sub-Saharan Africa. Previous research has shown that iNTS strains exhibit a pattern of gene loss that resembles that of host adapted serovars such as *Salmonella* Typhi and Paratyphi A. *Salmonella enterica* serovar Bovismorbificans was a common serovar in Malawi between 1997 and 2004.

Methodology: We sequenced the genomes of 14 Malawian bacteraemia and four veterinary isolates from the UK, to identify genomic variations and signs of host adaptation in the Malawian strains.

Principal Findings: Whole genome phylogeny of invasive and veterinary *S. Bovismorbificans* isolates showed that the isolates are highly related, belonging to the most common international *S. Bovismorbificans* Sequence Type, ST142, in contrast to the findings for *S. Typhimurium*, where a distinct Sequence Type, ST313, is associated with invasive disease in sub-Saharan Africa. Although genome degradation through pseudogene formation was observed in ST142 isolates, there were no clear overlaps with the patterns of gene loss seen in iNTS ST313 isolates previously described from Malawi, and no clear distinction between *S. Bovismorbificans* isolates from Malawi and the UK. The only defining differences between *S. Bovismorbificans* bacteraemia and veterinary isolates were prophage-related regions and the carriage of a *S. Bovismorbificans* virulence plasmid (pVIRBov).

Conclusions: iNTS *S. Bovismorbificans* isolates, unlike iNTS *S. Typhimurium* isolates, are only distinguished from those circulating elsewhere by differences in the mobile genome. It is likely that these strains have entered a susceptible population and are able to take advantage of this niche. There are tentative signs of convergent evolution to a more human adapted iNTS variant. Considering its importance in causing disease in this region, *S. Bovismorbificans* may be at the beginning of this process, providing a reference against which to compare changes that may become fixed in future lineages in sub-Saharan Africa.

Citation: Bronowski C, Fookes MC, Gilderthorp R, Ashelford KE, Harris SR, et al. (2013) Genomic Characterisation of Invasive Non-Typhoidal *Salmonella enterica* Subspecies *enterica* Serovar Bovismorbificans Isolates from Malawi. PLoS Negl Trop Dis 7(11): e2557. doi:10.1371/journal.pntd.0002557

Editor: Ruifu Yang, Beijing Institute of Microbiology and Epidemiology, China

Received: July 5, 2013; **Accepted:** October 11, 2013; **Published:** November 14, 2013

Copyright: © 2013 Bronowski et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The MRC funded 454 sequencing (Grant code G0600805, awarded to JW) and CB through a MRC capacity building studentship (Grant code G0500534, awarded to CAH and CW), while Illumina sequencing was funded through the Wellcome Trust under grant WT098051 (NRT) (<http://www.mrc.ac.uk/index.htm>; <http://www.wellcome.ac.uk>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: nrt@sanger.ac.uk

9 These authors contributed equally to this work.

† NRT and CW also contributed equally to this work.

Introduction

Invasive Non-typhoidal *Salmonella* (iNTS) are a major cause of morbidity and mortality in sub-Saharan Africa. Especially in young children, iNTS are either the first or second most common cause of bacteraemia [1,2], meningitis and septic arthritis [3,4] with high morbidity. HIV infection is the primary risk factor for iNTS bacteraemia in adults, and it has been suggested that iNTS

emerged together with the HIV pandemic in sub-Saharan Africa [5]. The most important clinical risk factors for iNTS disease in children are malnutrition, malaria and anaemia, with one in five cases of NTS bacteraemia in children also associated with HIV infection [2,6,7]. There is considerable interest in identifying any underlying bacterial genetic basis for the apparent increase in invasiveness and transmission of African NTS strains.

Author Summary

Bacteraemia and meningitis caused by non-typhoidal *Salmonella* (including serovars Typhimurium, Enteritidis and Bovismorbificans) are a serious health issue in sub-Saharan Africa, particularly in young children and HIV-infected adults. Previous work has indicated that a distinct *S. Typhimurium* sequence type, ST313, has evolved and spread in these countries, and may be more human-adapted than isolates found in the developed world. We therefore investigated the genomes of *Salmonella enterica* serovar Bovismorbificans bacteraemia isolates from Malawi and compared them to genomes of veterinary *S. Bovismorbificans* isolates from the UK using Next Generation Sequencing Technology and subsequent genomic comparisons to establish if there is a genetic basis for this increase in invasive disease observed among African NTS. Contrary to the previous findings for *S. Typhimurium*, where a distinct ST is found only in sub-Saharan Africa, we discovered that the *S. Bovismorbificans* isolates from Malawi belong to the most common ST of the serovar and the genome is highly conserved across all sequenced isolates. The major differences between UK veterinary and African human isolates were due to prophage regions inserted into the genomes of African isolates, coupled with a higher prevalence of a virulence plasmid compared to the UK isolates.

Strain collections of iNTS isolates from Africa are dominated by the serovars Typhimurium and Enteritidis [8–12]. However a seven year study of iNTS isolates associated with bacteraemia in Malawi showed that *S. Bovismorbificans* was the third most common serovar, with 46 cases, which accounts for 1% of the total number of NTS isolates [11]. In contrast to this, a study of *Salmonella* bacteraemia in developed countries (Finland, Denmark, Canada and Australia) showed that among 490 bacteraemia NTS isolates, isolated between 2000 and 2007, only one was *S. Bovismorbificans* (0.2%) [13]. However, *S. Bovismorbificans* has been found responsible for gastroenteritis outbreaks: in Malaysia between 1973 and 1996 *S. Bovismorbificans* accounted for 2–11% of salmonellosis cases [14,15] as well as isolated outbreaks all over Europe and around the world [16,17][18], *S. Bovismorbificans* phage type 32 (PT32) [19,20].

It has been shown that bacteraemia isolates of *S. Typhimurium* from Kenya and Malawi belong to a distinct Multi Locus Sequence Typing (MLST) group, ST313, that harbours a specific repertoire of prophages and shows evidence of specific patterns of genome degradation with many parallels to human-specific *Salmonella* serovars such as *S. Typhi* and Paratyphi A, which cause acute invasive disease [21]. ST313 is significantly distant from the common gastroenteritis-associated *S. Typhimurium* ST19 [22]. These studies have raised the possibility that bacteremia-associated iNTS serovars that were previously able to infect a broad host range are becoming human-host adapted [23,24].

Multidrug resistance is also a significant factor in the emergence of iNTS strains in Africa, resulting in a reliance on fluoroquinolones [11,25]. While *S. Typhimurium* and Enteritidis isolates from Malawi exhibited resistance to commonly-used antimicrobials (including ampicillin, co-trimoxazole and chloramphenicol), iNTS *S. Bovismorbificans* isolates have remained comparatively susceptible to these commonly-used antimicrobials.

Here, we report the genome sequence of *S. Bovismorbificans* 3114 (ST142), a paediatric bacteraemia isolate from Malawi, and describe a detailed analysis of iNTS strains of *S. Bovismorbificans* causing disease in humans in Malawi and compare them to other

isolates from the same region and from veterinary isolates from the UK. We investigated whether there are markers of adaptation to the human host, similar to those described in other iNTS serovars from this region.

Materials and Methods

Bacterial strains and antimicrobial resistance profiling

Malawian *S. Bovismorbificans* isolates used in this study were taken from a previous study by Gordon *et al* [11] and date from 1997 to 2004. *S. Bovismorbificans* serovar designations for Malawian strains were confirmed by serotyping at the National *Salmonella* Reference Laboratory, Galway, Republic of Ireland. Veterinary strains of *S. Bovismorbificans* were obtained from Professor Paul Barrow (University of Nottingham), and were taken from a collection dating from the 1970s and 1980s. All *Salmonella* strains were stored in 10% (v/v) glycerol broth at -80°C . The antimicrobial susceptibility profiles of the four veterinary strains were determined by the disc diffusion method, in accordance with BSAC guidelines (<http://bsac.org.uk/wp-content/uploads/2012/02/Version-11.1-2012-Final.pdf>), using a total of 11 antimicrobials: (AML10 (amoxicillin 10 μg), AMC30 (amoxicillin/clavulanic acid 30 μg), CTX30 (cefotaxime 30 μg), CN 10 (gentamicin 10 μg), CIP 1 (ciprofloxacin 1 μg), W 2.5 (trimethoprim 2.5 μg), NA 30 (nalidixic acid 30 μg), RL25 (sulphamethoxazole 25 μg), C10 (chloramphenicol 10 μg), TET30 (tetracycline 30 μg), CXM 5 (cefuroxime sodium 5 μg), RD 2 (rifampicin 2 μg), CAZ30 (ceftazidime 30 μg), S 25 (streptomycin 25 μg). The susceptibility profiles of the human *S. Bovismorbificans* isolates from Malawi have been determined previously, in accordance with BSAC guidelines [11].

Genomic DNA extraction and genome sequencing

Salmonella strains were cultured in Luria broth overnight at 37°C shaking at 200 rpm. Genomic DNA extractions were performed using the Wizard Genomic DNA Purification Kit (A1120, Promega, Madison, USA) as described in the manufacturer's instructions.

The genome of *S. Bovismorbificans* strain 3114 was sequenced using the Roche 454 Genome Sequencer FLX (GS-FLX) following the manufacturer's instructions (Roche 454 Life Science, Branford, CT, USA). In brief, each sample was made into both a paired-end and fragment library using the standard FLX chemistry for 454. Fragment libraries were prepared by fragmentation, attachment of adapter sequences, refinement of the ends and selection of adapted molecules. Paired-end libraries were produced by hydroshear shearing, circularisation, addition of adapters and selection, as for the fragment library. Both libraries were amplified by emPCR and fragment-containing beads were recovered and enriched. Sequencing primers were added and each library was deposited onto a quarter of a PicoTiterPlate plate and sequenced.

Multiplexed Illumina standard libraries were prepared for *S. Bovismorbificans* 3114 and 17 additional strains following standard protocols with 200 bp inserts and sequenced on the Illumina Genome Analyzer II. Paired end sequence runs were performed with 54 bp read length. Raw sequence data is submitted to the public data repository, ENA, under accession ERP000181.

S. Bovismorbificans strain 3114 genome sequence assembly

For *S. Bovismorbificans* 3114 454 data, reads from the fragment and paired-end libraries were de-novo assembled into contigs

using the Roche 454 Newbler assembler (version 2.0.01.12) with default settings.

Illumina data was then used to extend and order the 454-assembled contigs using the PAGIT package [26] as follows: 454 contigs were extended using ICORN [26], and the resulting contigs were ordered and orientated with respect to the genome of *S. Typhimurium* LT2 using ABACAS [27]. Finally, gap closure was attempted where possible using IMAGE [26].

For each scaffold-contig in turn, putative coding sequences (CDSs) were predicted using Glimmer version 3.02 (<http://www.cbcb.umd.edu/software/glimmer/>). A further in-house Perl script was then used to identify and correct those CDSs likely to have been split due to sequencing errors when handling homopolymer repeats. This involved BLASTP alignment of CDS protein translations against a database of translations generated from previously annotated *Salmonella* genomes, the identifications of likely indels within homopolymer regions, the modification of coding sequence feature positions to correct errors, and the merging of relevant CDSs. Where such modification occurred, this was recorded as metadata (in the form of the eventual GenBank feature note field). Such CDSs were also marked with the exception flag set to 'low-quality sequence region' for the final GenBank submission to signify poor quality sequencing.

A putative function was then assigned to each gene by BLASTn (NCBI Blast 2.2.17) comparison with a database of sequences generated from the previously annotated genome of *S. Typhimurium* LT2. Putative tRNA genes were detected using tRNAscan-SE 1.23 (<ftp://selab.janelia.org/pub/software/tRNAscan-SE/>). A pseudochromosome, consisting of a concatenation of contigs arranged into scaffolds, with 100 Ns separating adjoining scaffolds, was prepared for comparison purposes; the final version of the 3114 genome was manually curated using Artemis [28,29].

The *S. Bovismorbificans* 3114 chromosome has been submitted to EMBL under accession number HF969015, and its 93.8 kb virulence plasmid under accession number HF969016.

S. Bovismorbificans Illumina genome assembly

Illumina sequence data for the 17 additional genomes was assembled as follows: for each strain, Velvet [30] was used to create multiple assemblies by varying the kmer size between 66% and 90% of the read length. From these assemblies, the one with the best N50 was chosen and contigs which were shorter than the insert size length were removed. An assembly improvement step was then run on the chosen assembly. The contigs of the assembly were scaffolded by iteratively running SSPACE [31]. Then gaps identified as 1 or more N's, were targeted for closure by running 120 iterations of GapFiller [32]. Finally, the reads were aligned back to the improved assembly using SMALT (<http://www.sanger.ac.uk/resources/software/smalt/>) and a set of statistics was produced for assessing the QC of the assembly.

All of the software developed is freely available for download from GitHub (<https://github.com/sanger-pathogens>) under an open source license, GNU GPL 3. The improvement step of the pipeline is also available as a standalone Perl module from CPAN (<http://search.cpan.org/~ajpage/>) (see Table S1 for assembly data and statistics).

Pseudogene analysis

Pseudogenes were identified, using ACT comparisons [33], by comparing the genome of strain 3114, first to *S. Typhimurium* LT2 and then to the genomes of *S. Typhimurium* D23580, SL1344 and DT104. Pseudogenes were identified according to whether CDS showed frameshift mutations, missing N- or C-terminals or carried nonsense mutations. Once pseudogenes were

identified in the 3114 genome, their orthologous sequences were checked in the assemblies of a further six *S. Bovismorbificans* isolates, from both Malawi (3180, D1253, D993, A1668,) and the UK (653308, 276608). These isolates were chosen as representatives of distinct subclades in the tree. In some cases it was not possible to identify mutations due to gaps in the sequence; these are highlighted in Table S5.

Multi Locus Sequence Typing (MLST)

MLST sequences were obtained from Illumina reads and sequence types were assigned through the MLST website (<http://www.mlst.net/>). Ambiguous results for some individual loci were subsequently confirmed by PCR amplification of the locus and sequencing of the PCR product (Beckman Coulter). In order to build the MLST-based phylogenetic tree of Figure S1, the concatenated sequences of the seven MLST loci of *S. Bovismorbificans* 3114 and the most common *S. enterica* STs from published databases were loaded into SeaView v3.2 [34]. The phylogeny was reconstructed using PhyML [35] within the Seaview package, and FigTree v1.3.1 [36] was used to edit and label the final figure.

Construction of a pan genome pseudomolecule

For the purpose of mapping and visualization of the genomic content of all *S. Bovismorbificans* samples, a pseudomolecule was constructed comprising the reference 3114 genome (chromosome and virulence plasmid) and all non-redundant accessory regions found by tblastx in each sample assembly with respect to the others in an iterative manner. Briefly we performed pairwise comparisons, firstly of one isolate against the reference sequence (genome and its plasmid). Regions in the comparator that were not present in the reference were identified and added to the end of the reference sequence to form a pan genome pseudomolecule. This was repeated in an iterative process involving manual curation of the sequences to be included in the growing pseudo molecule.

Read mapping, single nucleotide polymorphism (SNP) calling and construction of the phylogenetic tree of the *S. Bovismorbificans* sample set

Mapping of illumina reads per sample was carried out against this resulting pseudomolecule using SMALT (<http://www.sanger.ac.uk/resources/software/smalt/>) without mapping to repeats. SNP calling was performed as previously described [37]. In order to construct a robust phylogenetic tree a Bayesian approach [38], which identifies high density SNPs and recombinant regions and ignores them when constructing the phylogeny, was used. A detailed list of sites removed from the chromosome, 48,423 bases in total, is summarised in Table S2 and the alignment of variant sites used to construct the final phylogenetic tree is presented in Table S3. In order to construct the phylogenetic tree shown in Figure 1 an initial tree using *S. Heidelberg* str SL476 (acc no. CP001120) (see Figure S1), as an outgroup was constructed. This identified the root position in the ingroup and final tree. Using this root position the final tree shown in Figure 1 was constructed using all 954 variant sites (Table S3) within the chromosome: A maximum likelihood approach (RAxML) was used to construct the initial bipartitions tree followed by a reconstruction of the SNPs onto the tree branches using delayed transformation (DELTRAN) parsimony [39].

Mapped illumina read data was saved in Bam format [40] and converted to coverage files (number of reads mapped to each base coordinate of the reference) with an in-house script. To aid visualisation the read depth per base position of each isolate against the pan-pseudomolecule reference sequence was




Figure 1. Phylogenetic tree of *S. Bovismorbificans* isolates and visualization of the Bovismorbificans pan-genome. Maximum likelihood phylogenetic tree of *S. Bovismorbificans* isolates (left), Bootstrapping values below 100% are shown and branch length corresponds to SNPs, proportional to the shown scale (left). Colour-coded information on each strain follows to the right, including origin (A = Adult, C = Child, V = Veterinary), year of isolation (an exact date of isolation for the veterinary isolates is not known (ND) but the collection predates the 1980s), ST, antimicrobial resistance profile (RL = sulphamethoxazole, CXM = cefuroxime, RD = rifampicin, amoxicillin (AML), gentamicin (CN), trimethoprim (W), chloramphenicol (C), tetracycline (TET), streptomycin (S)) and presence or absence of the virulence plasmid pVIRBov (see key for further details, bottom). The shaded area (right) shows base positions of the pan-genome pseudomolecule (depicted above) coloured white, grey or black representing 0 (white; absent) 1–14 (grey; partially present) or 15 or more (black; present) read coverage per base for each sample. The pan-genome pseudomolecule is shown (right top) consisting of the chromosome of isolate 3114 genome (ochre shading) the virulence plasmid pVIRBov (blue shading) and concatenated accessory regions (green shading). Significant regions of variation (see methods) are marked on the pan-genome pseudomolecule: RODs 13, 14, 34 (red boxes) and SPI-7 (dark green).
doi:10.1371/journal.pntd.0002557.g001

constructed (Figure 1). Base positions with 0 or 1–14 reads mapped were coloured white or grey, respectively. Base positions with 15× coverage or greater are coloured black. The cutoff of 15 or more times coverage per base position was selected because it was just below the minimum median coverage obtained across all of the isolates we sequenced (16 to 31× coverage [data not shown]; see Figure 1). Using the observed coverage regions >4000 bps showing a significant deviation from the median coverage were identified by manual curation and checked against the genome assembly.

Accession numbers

The raw sequence data is available under the accession number ERP000181 at the European Nucleotide Archive, ENA. The

sequence and annotation data for *S. Bovismorbificans* strain 3114 chromosome and virulence plasmid, pVIRBov are available from ENA under accession numbers HF969015-HF969016.

Results and Discussion

Phylogenomics of *S. Bovismorbificans* isolates

To establish a phylogenetic framework for the *S. Bovismorbificans* samples we sequenced the genomes of 18 isolates, 14 of which were derived from Malawian adults and children isolated between 1997 and 2004 at the Queen Elizabeth Hospital Blantyre, Malawi. Suspecting these could be clonal, we brought into the analysis the sequences of 4 further isolates of different origin (pigs and alpaca), geographical location (UK) and temporal isolation

Table 1. *S. Bovismorbificans* isolates used in this study.

Strain	Isolation year	Host	Age [#]	Outcome	pVIRBov	Antimicrobial Resistance profile	MLST ST*	ROD13	ROD14	ROD34	Accessory Genome Size (bp)
human											
3114	1997	child	ND	ND	+	RL_CXM_RD	142	+	+	+	0
3180	1997	child	ND	ND	+	RL_CXM_RD	142	+	+	+	38,420
3476	1997	child	ND	ND	+	RL_CXM_RD	142	+	+	+	131,557
D993	1999	child	ND	ND	+	CXM_RD	142SLV_1	+	+	+	110,972
D1253	1999	child	4M	ND	+	CXM_RD	142	+	+	+	5,577
D4451	2000	child	1Y11M	ND	+	RL_CXM_RD	142	+	+	+	4,791
D4891	2000	child	11M	ND	+	RL_CXM_RD	142SLV_2	+	+	+	4,791
A1104	1998	adult	ND	3	+	CXM_RD	142	+	+	+	4,791
A1608	1998	adult	ND	ND	+	RL_CXM_RD	142	+	+	-	7,893
A1668	1998	adult	ND	1	+	RL_CXM_RD	142	+	+	-	7,893
A16982	2002	adult	ND	2	+	RL_CXM_RD	142	+	+	+	4,735
A31126	2004	adult	23Y	1	+	RL_CXM_RD	142	+	+	+	34,498
A5893	1999	adult	35Y	ND	+	RL_CXM_RD	142	+	+	+	40,582
A8737	2000	adult	30Y	ND	+	RL_CXM_RD	142	+	+	+	5,695
veterinary											
499208	<1980	alpaca	N/A	N/A	-	AML_CN_W_RL_C_TET_CXM_RD_S	142	/	-	-	289,627
653308	<1980	pig	N/A	N/A	-	CXM_RD_S	142	/	-	-	88,266
276608	<1980	pig	N/A	N/A	-	TET_CXM_RD	142	/	-	-	121,149
51892776	<1980	pig	N/A	N/A	+	CXM_RD	142	-	-	-	36,589

The table summarizes properties of the isolates used in this study, including the presence or absence of ROD13, -14 and -34, the presence of the virulence plasmid pVIRBov and the size of the accessory genome in each of the additional 17 Illumina-sequenced *S. Bovismorbificans* genomes obtained in comparison to strain 3114. [#]M=months, Y=years; outcome 1=death, 2=survived, 3=unknown, ND=no data; N/A=not applicable; resistance profile=sulphamethoxazole (RL), cefuroxime (CXM), rifampicin (RD), amoxicillin (AML), gentamicin (CN), trimethoprim (W), chloramphenicol (C), tetracycline (TET), streptomycin (S); ST refers to the MLST sequence type as determined by Illumina sequencing and sequencing of PCR amplicons, *SLV=Single Locus Variant; ROD13/=partial or different ROD present. doi:10.1371/journal.pntd.0002557.t001

(1970s/80s) to provide context to investigate wider serovar variations. Genomic DNA from the *S. Bovismorbificans* isolates were assayed using either 454 or multiplex Illumina sequencing (see methods). The genome data of these sequences are summarised in Table 1. Only chromosomal SNPs were used to construct the maximum likelihood phylogenetic tree (see methods) shown in Figure 1 (left), for which the root branch (leading to sample 51892776) was previously identified by including an outgroup (see methods). Recombinant regions and regions that were unlikely to reflect the core phylogeny, such as prophage, were removed from this analysis (48,423 total sites; Table S2).

Amongst our samples, we found a total of 954 variable sites randomly distributed around the *S. Bovismorbificans* chromosome, which is approximately one SNP per 4,742 bp or just under 0.001% nucleotide divergence, within the core regions. It is evident that the human and animal isolates are intermixed. To give an idea of the level of nucleotide divergence within the core genome the animal isolate 51892776 closest to the root, was separated by 328 or 341 SNPs from the reference human isolate 3114 or most the divergent isolate shown in the tree, respectively. Consistent with this, we extracted the sequences of the MLST loci from the whole genome sequence data. All strains belonged to the major *S. Bovismorbificans* sequence type ST142 except two Malawian strains D993 and D4891 which were single locus variants (SLV) of ST142 (see Table 1) but were not found to be located on long branches on the tree.

It is evident from Figure 1 (left) that the human *S. Bovismorbificans* isolates taken in Malawi are phylogenetically extremely closely related, when compared to each other. This level of sequence divergence is comparable to the evolutionary distance between the *S. Typhimurium* lineages causing invasive disease in Africa [41] which form two distinct lineages (differentiated from each other by 455 SNPs), that are separated from the nearest gastroenteritis lineages by >700 SNPs [41]. However, when including the animal isolates from the UK it is apparent that this limited variation is a feature of *S. Bovismorbificans* as a serovar despite temporal, geographic and host differences. Also, in contrast to the *S. Typhimurium* lineages causing invasive disease, there was no clustering within the human samples with age or year of isolation.

Together these data suggested that the *S. Bovismorbificans* isolates causing invasive disease in Malawi, unlike *S. Typhimurium*, were not a specialised clade, at least according to the core phylogeny, therefore we looked at the accessory genome for clues to the observed differences in disease outcome for these isolates causing invasive disease in Malawi.

Accessory genomic regions within *S. Bovismorbificans* ST142 isolates

In order to visualise the variation across *S. Bovismorbificans* isolates we constructed a pan-genome. To do this we concatenated the whole genome sequence of strain 3114 (chromosome and

virulence plasmid) as well as the regions found to be variable present in one or more isolate, in a non-redundant manner (see methods). Figure 1 (right) shows the read coverage of all isolates included in this study mapped against the pan-genome pseudo-molecule (see methods).

There are three main regions of difference (RODs) in chromosome of strain 3114, denoted ROD_13, ROD_14 and ROD_34. These are the only significant regions of difference in the core genome being either absent or partially present in the four veterinary strains and variably distributed in the human isolates (Table 1 and Figure 1). They are predicted to encode prophage; ROD_34 and ROD_13 are highly similar to the *S. Typhimurium* prophage elements Gifsy-1 and Gifsy-2, respectively, and have therefore been termed Gifsy-like (See Table S4). ROD14 represents a novel 46.4 kb prophage inserted into a spermidine/putrescine operon on the *S. Bovismorbificans* 3114 genome (See below; Table S4).

A distinctive region of variation between human (carried in all) and animal samples (variably present) was a ~93 kb virulence plasmid, here named pVIRBov (Figure 2(B)). pVIRBov is highly similar to the *S. Typhimurium* LT2 virulence plasmid, pSLT (See Figure 2(B) and S2) and, like pSLT, carries the defining *spv* virulence gene cassette and the *pef* (plasmid-encoded fimbriae) operon mediating adhesion to murine intestinal epithelial cells [42]. Located downstream of the *pef* operon is the *rcK* (resistance to complement killing) gene. RcK is required by *S. Typhimurium* for survival in macrophages and for virulence in mice [43]. pVIRBov also shows a 7.463 kb deletion, and a 6.705 kb insertion, compared to pSLT. The deleted region contains a putative gene for single strand binding protein B (*ssbB*), as well as a number of putative genes encoding membrane-associated proteins. The insertion relative to pSLT includes a *pilA*-like gene (SBOV4711), *repC* (SBOV47701), a gene encoding a putative outer membrane protein (SBOV47871), *traJ* (SBOV48411), the primary activator of *tra* (polycistronic transfer) operon expression [44] and a number of hypothetical proteins. pVIRBov does not carry *rsk* (resistance to serum killing), thought to be associated with the control of serum resistance [45]. In contrast to a previous PCR based screen of *S. Bovismorbificans* isolates, these data show that 100% of the human bacteraemia isolates and only one in four of the UK veterinary isolates carry pVIRBov [46].

In pairwise comparisons with respect to the *S. Bovismorbificans* str 3114 genome, eight human isolates (D1253, D4891, D4451, A1104, A1608, A1668, A16892 and A8737) were almost identical in genomic content to the reference, with accessory regions of only 4–8 kb (summarised in Table 1). The veterinary isolate 499208 and the paediatric bacteraemia isolate 3476 both carry the largest accessory genomic regions, of ~290 kb and 132 kb, respectively (Table 1). The accessory genome of 3476 contains a ROD inserted at a t-RNA(Phe) -downstream of the CDS homologue to SBOV31771 in the 3114 strain-, showing high sequence homology to the SPI-7 of the human restricted pathogen *S. Typhi* CT18 (Figure 1, Figure S3). SPI-7 is a large mosaic pathogenicity island carrying a collection of virulence-related genes; versions of SPI-7 have been identified in *S. enterica* serovars Typhi, Paratyphi C, and Dublin [47–49]. This particular version of sample 3476 also encodes a putative Vi capsule although lacks the *sopE* phage of *S. Typhi* CT18. It also contains an operon related to carbohydrate metabolism and extracellular structure modifications (Figure S3). We did not find any genomic scar or any other evidence to show that this island might have been contained in any of the other human isolates or most recent ancestors.

Despite the existence of substantial accessory regions in half of the samples sequenced, they were mostly found to be unique to

single isolates without correlation to the phylogenetic inference or the disease outcome.

Comparative analysis of Pseudogene carriage amongst *S. Bovismorbificans* and *S. Typhimurium* isolates

In addition to gene gain, functional gene loss plays an important role in the adaptation of the *Salmonella* to different lifestyles, with host restricted *Salmonella* carrying over 200 pseudogenes [21,22,47,50–52] compared to their broad host range counterparts. It is also evident that the patterns of gene loss are nonrandom with nonsense mutations and frame-shifts being over-represented in genes that are associated with aspects of virulence or host interaction. The parallels in the patterns of pseudogene accumulation is also a feature of the iNTS *S. Typhimurium* isolate D23580, causing invasive disease in Malawi.

By comparing the genome of strain 3114 to those of *S. Typhimurium* D23580, SL1344 and DT104, a total of 43 pseudogenes were identified in *S. Bovismorbificans* 3114. Six further *S. Bovismorbificans* isolates, which were chosen as representatives of distinct groups on the phylogenetic tree were also analysed for pseudogene content (summarised results in Table S5).

Of the 43 pseudogenes identified, 15 (34.9%) were conserved in all of the six *S. Bovismorbificans* isolates tested, but intact in the three *S. Typhimurium* strains. There was no clear distinction in pseudogene carriage between human bacteraemia (Malawi) and veterinary (UK) *S. Bovismorbificans* isolates, with only a single pseudogene specific to Malawian isolates. Five (11.5%) pseudogenes have been identified as pseudogenes in all seven *S. Bovismorbificans* and all three of the *S. Typhimurium* isolates (Table S5).

Genes that are pseudogenes in all seven *S. Bovismorbificans* isolates tested, but intact in all three *S. Typhimurium* isolates (D23580, SL1344, DT104), include genes involved in sugar metabolism, a putative autotransporter of the haemagglutinin family (SBOV37821) and putative surface-exposed virulence protein BigA (SBOV35501).

We observed no clear link between pseudogene carriage and source (human and veterinary isolates). Although the extent of pseudogene formation in *S. Bovismorbificans* does not compare to the host adapted *Salmonella* serovars or to the iNTS *Typhimurium* D23580, there are tantalising glimpses that suggest *S. Bovismorbificans* as a species may carry pseudogenes, such as BigA that are consistent with host specialisation. What is clear, though, is that this has not been driven by the emergence of a new dominant lineage adapted to humans in Africa as we have seen before with *S. Typhimurium* ST313.

Detailed comparison of *S. Bovismorbificans* with other *S. enterica* genomes

Since this is the first time a *S. Bovismorbificans* genome has been described and to identify functions that may be involved in the apparent plasticity in pathogenicity we performed whole-genome comparison between *S. Bovismorbificans* and *S. Typhimurium* LT2. These comparisons revealed a high level of synteny and colinearity, with no inversions (Figure 3). A comparison of *S. Bovismorbificans* genome statistics with other serovars is summarised in Table 2. Figure 2(A) shows orthologous genes, identified by reciprocal fasta searches, in 10 *S. enterica* subspecies 1 strains from eight *Salmonella* serovars as well as wider members of the *Enterobacteriaceae*. This analysis showed that *S. Bovismorbificans* gene content broadly resembles those common to *S. enterica* subspecies 1 NTS serovars. Genome comparisons to *S.*

Figure 2. (A) Representation of the *S. Bovismorbificans* chromosome. From the outside in, the outer Circle 1 shows the size in base pairs. Circles 2 and 3 show the position of CDS transcribed in a clockwise and anti-clockwise direction, respectively. Circle 4 shows Regions of Difference (RODs) common to several NTS, including pathogenicity islands (blue), fimbrial operons (orange) and phages (pink), while Circle 5 shows (RODs) in *S. Bovismorbificans* that are different or absent from *S. Typhimurium* (magenta). Circles 6 to 20 show orthologous genes of *S. Bovismorbificans* (as determined by reciprocal FASTA analysis) in: *S. Typhimurium* (LT2), *S. Typhimurium* (D23580), *S. Typhimurium* (SL1344), *S. Enteritidis* (SEN), *S. Choleraesuis* (Schol), *S. Paratyphi A* (SpA), *S. Paratyphi C* (ParaC), *S. Typhi* (CT18), *S. Gallinarum* (SGAL) and *S. Arizonae* in red, *E. coli* (M1655) and *E. coli* (Sakai) in blue and *Yersinia enterocolitica* (YE), *Yersinia pestis* (YPSTB) and *Y. pestis* (YP91001) in green. Circle 21 shows a plot of G+C content (in a 10-kb window). Circle 22 shows a plot of GC skew ($(G - C)/(G + C)$; in a 10-kb window). Genes in circles 3 and 4 are color-coded according to the function of their gene products: dark green, membrane or surface structures; yellow, central or intermediary metabolism; cyan, degradation of macromolecules; red, information transfer/cell division; cerise, degradation of small molecules; pale blue, regulators; salmon pink, pathogenicity or adaptation; black, energy metabolism; orange, conserved hypothetical; pale green, unknown; and brown, pseudogenes. **(B). The virulence plasmid of *S. Bovismorbificans* 3114 pVIRBov.** From the outside: Circle 1 shows the size in basepairs, Circle 2 and 3 show CDSs in a clockwise and anti-clockwise direction, respectively. Circle 4 shows orthologous genes of pVIRBov in pSLT of *S. Typhimurium* LT2 (red) as determined by reciprocal fasta analysis. Circle 4 shows a plot of G+C content (in a 10-kb window). Circle 5 shows a plot of GC skew ($(G - C)/(G + C)$; in a 10-kb window). Genes in circles 2 and 3 are colour-coded according to the function of their gene products: dark green, membrane or surface structures; cyan, degradation of macromolecules; red, information transfer/cell division; pale blue, regulators; salmon pink, pathogenicity or adaptation; black, energy metabolism; orange, conserved hypothetical; pale green, unknown.

doi:10.1371/journal.pntd.0002557.g002

S. Typhimurium LT2 show that, while SPI-1,-2,-4,-5,-9 and -11 are largely synonymous, SPI-3,-6,-10 and -12 show deletions compared to the genome of *S. Typhimurium* LT2. Of note is SPI-6, formerly known as SCI (*Salmonella enterica* centisome 7 island), which is approximately 10.6 kb in size, compared to the 47 kb SPI-6 in the genome of *S. Typhimurium* LT2, and simply retains part of the fimbrial *saf* operon while lacking the Type VI secretion system (T6SS) encoded by this island. The T6SS is thought to play a role in adaptation to different lifestyles and environments, particularly animal hosts. SPI-6 T6SS was found to be absent from serovars Enteritidis, Gallinarum, Agona, Javiana, Virchow and IIIb 61:1, v:1,5,(7) [53]. Like *S. Typhimurium* LT2, SPI-13 and -14, are largely absent from *S. Bovismorbificans* [54] as are SPI-15 and -17 (Figure 3 see Table S6 for details on SPI repertoires)

S. Bovismorbificans 3114 and *S. Typhimurium* LT2 share the same repertoire of 13 fimbrial operons (*stf*, *saf*, *stb*, *fim*, *stc*, *std*, *lpf*, *stj*, *sth*, *bef*, *sti*, *csf* and *pef*) although *safA* of the *saf* operon is absent from the genome of strain 3114. The positions of the fimbrial operons within the *S. Bovismorbificans* 3114 genome are summarized in Figure 3.

Comparison of *S. Bovismorbificans* with other *S. enterica* genomes: Regions of difference (RODs)

Regions of difference (RODs) were defined as insertions (or replacements) in the genome of *S. Bovismorbificans* 3114 when compared to published *S. Typhimurium* genomes (see methods; summarized in Table S4). A total of 27 RODs were identified many of which were predicted to encode proteins of unknown

function. The most significant class of RODs were those related to prophage elements (ROD7,-12, -13, -14, -17, -21, -30, -31, 34; ROD 13, -14 and -34 are described above). Prophages are important sources of genomic variation in *Salmonella*, with most serovars being polylysogenic [55,56]. Cryptic prophages have been shown to contribute to bacterial survival in adverse environments. They have been shown to help bacteria overcome acid, osmotic and oxidative stresses, influence growth and biofilm formation and contribute significantly to resistance to β -lactams and quinolones [57].

In comparison to the genome of *S. Typhimurium* LT2, the genome of *S. Bovismorbificans* 3114 has a number of deletions or variations in regions related to common *Salmonella* prophages. There are no putative genes matching the common *Salmonella* prophage Fels-1 and Fels-2, with the exception of the Fels-1 *ybjP* gene. Also absent, compared to *S. Typhimurium* LT2, are inducible prophages Gifsy-1 and Gifsy-2, which have been replaced by prophage-like RODs 34 and 13 respectively (See above; Table S4). Although, ROD13 presents a partial match to Gifsy-2, it does not carry the same genetic cargo *sodCI* which is associated with intracellular survival [58] or *gtgA*, which together with *sodCI* and *gtgB* is also absent from Gifsy-1 of *S. Typhi* [59]. ROD34 is 45.8 kb in size and carries Gifsy-1 like regions in both terminal regions, as well as one Fels-1 like region. ROD14 represents a novel prophage 46.4 kb in size with some similarities to a predicted *E. coli* (UMKN88) phage and to Bacteriophage P27. The cargo of ROD14 largely constitutes hypothetical proteins with the exception of the SPI-2 effector *sifA* gene (SBOV11471) which is essential for Sif formation, a process




Figure 3. ACT comparison (<http://www.sanger.ac.uk/Software/ACT>) between *S. Bovismorbificans* 3114 and *S. Typhimurium* LT2. Showing amino acid matches between the complete six-frame translations (computed using TBLASTX) of the whole-genome sequences of *S. Bovismorbificans* and *S. Typhimurium* (LT2). Forward and reverse strands of DNA are shown for each genome (light grey horizontal bars). The red bars between the DNA lines represent individual TBLASTX matches, with inverted matches colored blue. The position of all the fimbrial operons marked in orange, the positions of *Salmonella* pathogenicity islands (SPI) are marked in blue, the position of prophages inserted into the genome are marked in pink. Analogous features are coloured the same.

doi:10.1371/journal.pntd.0002557.g003

Table 2. Properties of the *S. Bovismorbificans* 3114 chromosome compared to other *S. enterica* chromosomes [22,47,51,72].

	Bovismorbificans	Typhimurium	Typhimurium	Typhi	Enteritidis	Gallinarum
strain	3114	D23850	LT2	CT18	P125109 (PT4)	287/91
Size (bp)	4677483	4879400	4857432	4809037	4685846	4658697
percent G&C	52.19	52.19	52.22	52.09	52.17	52.2
No of CDS	4671	4521	4451	4599	4318	4274
coding density	86.60%	86.30%	86.80%	87.60%	85.50%	79.90%
average gene size	877	947	947	958	953	939
pseudogenes	43	77	25	204	113	309

doi:10.1371/journal.pntd.0002557.t002

linked to SCV (*Salmonella* Containing Vacuole) integrity [60,61]. The remaining prophage regions show no similarity to other *Salmonella* prophage but are present in all of the strains we have sequenced, regardless of source (summarised in Table S4)

S. Bovismorbificans ST142 antibiotic resistance phenotypes and genotypes

Multidrug resistance is a serious problem in sub-Saharan Africa. *S. Typhimurium* and *S. Enteritidis* isolates from Malawi exhibit extensive resistance profiles. The empirical treatment for adults with sepsis in Malawi was chloramphenicol and benzyl penicillin. With the emergence of chloramphenicol resistance in *S. Typhimurium* isolates in 2002, treatment was switched to ciprofloxacin and parenteral gentamicin was added. While *S. Typhimurium* isolates have been resistant to ampicillin and trimethoprim-sulphamethoxazole for a long time, a dramatic increase of resistance to ampicillin, trimethoprim-sulphamethoxazole and chloramphenicol was observed in *S. Enteritidis* isolates in 1999 [62].

Phenotypic antibiotic resistance profiles (Table 1 and Figure 1) were obtained for all *S. Bovismorbificans* samples in this study. Of the 14 Malawian *S. Bovismorbificans* isolates, 11 showed resistance against sulphamethoxazole, cefuroxime and rifampicin, while three isolates were resistant to cefuroxime and rifampicin only. Contrary to the findings for *S. Typhimurium* and *S. Enteritidis*, *S. Bovismorbificans* isolates remain susceptible to chloramphenicol and ampicillin, and resistance to sulphamethoxazole and cefuroxime follows no discernible temporal distribution.

Table 3 and Table S7 summarize putative resistance related genes identified in both the core and accessory genomic regions of all *S. Bovismorbificans* isolates. Consistent with other studies in enteric bacteria, linking antibiotic resistance phenotype and genotype was problematic [63]. However, we were able to identify

a number of putative β -lactamase genes in *S. Bovismorbificans* that may explain the resistance to cephalosporins, such as Cefuroxime. Moreover all the *S. Bovismorbificans* isolates (including the veterinary ones) carry the mutation in the *rpoB* gene associated with resistance to rifampicin [64–66] (Figure S4 shows the *rpoB* gene alignment of strain 3114 together with those of *S. Typhimurium* LT2 and DT104). Despite phenotypic resistance to sulphamethoxazole no *sul* genes could be identified in any of the 14 Malawian *S. Bovismorbificans* isolates to explain this.

Prevalence of tuberculosis (TB) is high in HIV-infected patients [67], and co-infection with invasive NTS and TB is common [68]. Rifampicin is the standard treatment for TB. Ours and previous data show that all of the NTS isolates, regardless of serovar, were resistant to rifampicin [11]. It is not possible to comment on whether co-infection and treatment for TB might be a causal mechanism for the emergence of resistance among *S. Bovismorbificans* or simply allowed an already resistant *S. Bovismorbificans* to exploit this niche. There is, however, strong evidence antimicrobial resistance, particularly to chloramphenicol in the case of *S. Typhimurium* have been key drivers in the spread of *Salmonella* pathovars across Africa [41].

A number of additional putative resistance genes were identified in the *S. Bovismorbificans* core genome, including those directed against aminoglycosides (*aadA*), streptomycin/spectinomycin (*aphA*) and trimethoprim (*dhfr1*) (Table S7).

For completeness the four veterinary UK isolates compared to the human isolates showed an even more diverse antimicrobial resistance profiles (summarised in Table 1), some of them showing an extensive array of resistance related genes, perhaps associated with the type of antibiotics and dosages used in the UK at the time they were isolated.

Table 3. Antimicrobial resistance genes identified in the *S. Bovismorbificans* genome.

Resistance gene	Mechanism of resistance	Resistance to*	SBOV CDS	DT104 CDS
<i>aadA</i>	streptomycin/spectinomycin adenylyltransferase	SPT, STR	SBOV12521	SDT1236
<i>aphA</i>	aminoglycoside phosphotransferase	KAN	SBOV43311	SDT4236
<i>dhfr1</i>	dihydrofolate reductase	TMP	SBOV00351	SDT0092
putative β -lactamase	β -lactamases	PENs	SBOV25431	SDT2527
β -lactamase domain			SBOV29851	SDT2944
putative β -lactamase			SBOV38301	SDT3717

This table summarizes antimicrobial resistance genes identified in the *S. Bovismorbificans* core genome in comparison to the *S. Typhimurium* DT104 genome. *SPT = spectinomycin, STR = streptomycin, TMP = trimethoprim, KAN = kanamycin, PENs = penicillins.

doi:10.1371/journal.pntd.0002557.t003

Conclusion

In conclusion all *S. Bovismorbificans* isolates included in this study showed extremely close phylogenetic relationships regardless of source, place of isolation, host or disease outcome, even though morbidity and mortality caused by NTS is much more severe in sub-Saharan Africa and the developing world [22,68]. Genome comparisons between the Malawian bacteraemia and UK veterinary isolates showed few clear differences. In our study, all of the bacteraemia isolates from Malawi were of the most prevalent *S. Bovismorbificans* sequence type, ST142.

Unlike iNTS *S. Typhimurium* isolates causing invasive disease in Malawi there is no evidence that functional gene loss was a significant feature of the evolution and adaptation to a more invasive lifestyle for African *S. Bovismorbificans* isolates. The only differences from those strains circulating elsewhere were in the mobile genome, largely prophage, and the presence of the virulence plasmid (only in one of four of the UK veterinary samples). However comparing the accessory genomic variations of the African *S. Bovismorbificans* isolates, such as the apparently random presence or absence of SPI-7, it strongly suggested that those causing disease originate from a mixed population of bacteria circulating within the region and that invasive disease by this serovar was caused by multiple sporadic independent bacteraemia infections.

All isolates, regardless of source, appear to display multiple phenotypic and genotypic drug resistance markers. In Malawi this is likely to have been essential to colonise a susceptible population, which tend to take regular antibiotic therapy. Although there is no obvious sign of convergent evolution to a more human adapted iNTS variant of *S. Bovismorbificans*, these strains -considering their importance in causing disease in this region-, may be at the very beginning of this process and so this study provides the reference point against which to compare changes that may become fixed in future lineages in sub-Saharan Africa. This study also highlights the likely importance of the patterns of evolutionary change we have previously highlighted in *S. Typhimurium* and show how, given the opportunity, multiple *Salmonella* serovars are able to cause more acute disease in susceptible populations.

Supporting Information

Figure S1 Concatenated MLST sequences of *S. enterica* subsp. I published on the MLST database (www.mlst.net). Tip labels show major lineages of the *Salmonella enterica* subsp. I serovar identified (ST11-*S. Enteritidis*, ST15-*S. Heidelberg*, ST19-*S. Typhimurium* and ST142-*S. Bovismorbificans*). *S. Typhi* ST1 has been included as an outlier.
(TIF)

Figure S2 ACT comparison (<http://www.sanger.ac.uk/Software/ACT>) between *S. Bovismorbificans* virulence plasmid pVIRBov (top) and *S. Typhimurium* LT2 virulence plasmid pSLT (AJ011572, bottom). Showing amino acid matches between the complete six-frame translations (computed using TBLASTX) sequences of pVIRBov and pSLT. Forward and reverse strands of DNA are shown for each genome (light grey horizontal bars). The blue bars between the DNA lines represent individual TBLASTX matches, with inverted matches colored red. All genes present are colour-coded according to the function of their gene products: dark green, membrane or surface structures; cyan, degradation of macromolecules; red, information transfer/cell division; pale blue, regulators; salmon pink, pathogenicity or adaptation; black, energy metabolism; orange,

conserved hypothetical; pale green, unknown. Analogous features are coloured the same.

(TIF)

Figure S3 A SPI7 island on the accessory genome of *S. Bovismorbificans* 3476. An EasyFig representation [69] showing comparison between the sequence of the reference *S. Bovismorbificans* str 3114 (A) at the location where the SPI7 island of sample 3476 (B) is inserted on its own genome and with respect to *S. Typhi* CT18 (C). The new 97 kb SPI7 island (B) is most similar to that of *S. Typhi* CT18 (C), containing an operon extra (genes in orange, marked B1) involved in carbohydrate modifications.

(TIF)

Figure S4 ClustalW2 alignment of *rpoB* from *S. Typhimurium* LT2, DT104 and *S. Bovismorbificans* 3114. Snapshot of ClustalW2 alignment [70,71] of a section of the predicted amino acid sequences of *rpoB* from *S. Typhimurium* LT2, *S. Typhimurium* DT104 and *S. Bovismorbificans* 3114, highlighting the single amino acid change detected in 3114.

(TIFF)

Figure S5 Putative function of CDS in *S. Bovismorbificans* accessory genomes according to blastx, measured in kilobases (kb) (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>).

(TIF)

Table S1 Assembly data and statistics for Illumina sequenced genomes of *S. Bovismorbificans* isolates.

(XLSX)

Table S2 Nucleotide sites masked when reconstructing the phylogeny of *S. Bovismorbificans* isolates.

(XLS)

Table S3 SNP profile for all *S. Bovismorbificans* isolates sequenced in this study.

(XLS)

Table S4 Regions of difference (RODs) determined by ACT comparison of *S. Bovismorbificans* 3114 and *S. Typhimurium* LT2.

(DOCX)

Table S5 Summary of pseudogenes identified in strain 3114.

(DOCX)

Table S6 Comparison of *Salmonella* Pathogenicity Islands (SPI) repertoire of *S. Bovismorbificans* 3114 and *S. Typhimurium* LT2.

(DOCX)

Table S7 Resistance related genes identified in *S. Bovismorbificans* samples.

(XLSX)

Acknowledgments

We would like to thank Theresa Feltwell (Wellcome Trust Sanger Institute) and Dr Margaret Hughes (CGR - UoL) who were involved in Illumina sequencing and Roche 454 sequencing, respectively. We would also like to thank Dr Ian Goodhead for help with genome curation and submission to the ENA database. We would further like to acknowledge Ms Winifred Dove and Mrs Amanda Hall for their help with antimicrobial susceptibility testing, serotyping and help with strain information. We would also like to thank Professor Paul Barrow for providing us with the veterinary *S. Bovismorbificans* isolates.

Author Contributions

Conceived and designed the experiments: CB MCF CW NRT CAH PW JW. Performed the experiments: CB MCF. Analyzed the data: CB MCF

RG KEA NRT CW MAG NH. Contributed reagents/materials/analysis tools: KEA NH SRH MAG AP JW NRT CW. Wrote the paper: CB CW MCF PW NRT.

References

- Bahwere P, Levy J, Hennart P, Donnen P, Lomoyo W, et al. (2001) Community-acquired bacteremia among hospitalized children in rural central Africa. *Int J Infect Dis* 5: 180–188.
- Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, et al. (2005) Bacteremia among children admitted to a rural hospital in Kenya. *N Engl J Med* 352: 39–47.
- Graham SM (2002) Salmonellosis in children in developing and developed countries and populations. *Curr Opin Infect Dis* 15: 507–512.
- Lavy CB, Peek AC, Manjolo G (2005) The incidence of septic arthritis in Malawian children. *Int Orthop* 29: 195–196.
- Okoro CK, Kingsley RA, Connor TR, Harris SR, Parry CM, et al. (2012) Intracontinental spread of human invasive *Salmonella* Typhimurium pathovariants in sub-Saharan Africa. *Nat Genet* 44: 1215–1221.
- Green SD, Cheesbrough JS (1993) *Salmonella* bacteraemia among young children at a rural hospital in western Zaire. *Ann Trop Paediatr* 13: 45–53.
- Graham SM, Molyneux EM, Walsh AL, Cheesbrough JS, Molyneux ME, et al. (2000) Nontyphoidal *Salmonella* infections of children in tropical Africa. *Pediatr Infect Dis J* 19: 1189–1196.
- Kassa-Kelembho E, Mbolidi CD, Service YB, Morvan J, Minssart P (2003) Bacteremia in adults admitted to the Department of Medicine of Bangui Community Hospital (Central African Republic). *Acta Trop* 89: 67–72.
- Kariuki S, Revathi G, Kariuki N, Kiiru J, Mwituria J, et al. (2006) Characterisation of community acquired non-typhoidal *Salmonella* from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. *BMC Microbiol* 6: 101.
- Gilks CF, Brindle RJ, Otieno LS, Simani PM, Newnham RS, et al. (1990) Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. *Lancet* 336: 545–549.
- Gordon MA, Graham SM, Walsh AL, Wilson L, Phiri A, et al. (2008) Epidemics of invasive *Salmonella enterica* serovar enteritidis and *S. enterica* Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. *Clin Infect Dis* 46: 963–969.
- Sigauque B, Roca A, Mandomando I, Morais L, Quinto L, et al. (2009) Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. *Pediatr Infect Dis J* 28: 108–113.
- Laupland KB, Schonheyder HC, Kennedy KJ, Lyytikainen O, Valiquette L, et al. (2010) *Salmonella enterica* bacteraemia: a multi-national population-based cohort study. *BMC Infect Dis* 10: 95.
- Lee WS, Puthucherry SD, Boey CC (1998) Non-typhoid *Salmonella* gastroenteritis. *J Paediatr Child Health* 34: 387–390.
- Jegathesan M (1984) *Salmonella* serotypes isolated from man in Malaysia over the 10-year period 1973–1982. *J Hyg (Lond)* 92: 395–399.
- Gilsdorf A, Jansen A, Alpers K, Dieckmann H, van Treeck U, et al. (2005) A nationwide outbreak of *Salmonella* Bovismorbificans PT24, Germany, December 2004–March 2005. *Euro Surveill* 10: E050324 050321.
- Puohiniemi R, Heiskanen T, Siitonen A (1997) Molecular epidemiology of two international sprout-borne *Salmonella* outbreaks. *J Clin Microbiol* 35: 2487–2491.
- Schiellerup P, Neimann J, Hald TM, Ethelberg S (2001) [Outbreak of *Salmonella* Bovismorbificans infection]. *Ugeskr Laeger* 163: 5683.
- Stafford RJ, McCall BJ, Neill AS, Leon DS, Dorricott GJ, et al. (2002) A statewide outbreak of *Salmonella* bovisorbificans phage type 32 infection in Queensland. *Commun Dis Intell* 26: 568–573.
- Nastasi A, Mammina C, Aleo A (1994) Epidemic dissemination of *Salmonella enterica* spp. *enterica* serovar Bovismorbificans in southern Italy in the years 1989–1991. *Eur J Epidemiol* 10: 81–84.
- Holt KE, Thomson NR, Wain J, Langridge GC, Hasan R, et al. (2009) Pseudogene accumulation in the evolutionary histories of *Salmonella enterica* serovars Paratyphi A and Typhi. *BMC Genomics* 10: 36.
- Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, et al. (2009) Epidemic multiple drug resistant *Salmonella* Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. *Genome Res* 19: 2279–2287.
- Moran NA, Plague GR (2004) Genomic changes following host restriction in bacteria. *Curr Opin Genet Dev* 14: 627–633.
- Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA (2012) Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. *Lancet* 379: 2489–2499.
- Kariuki S, Revathi G, Kariuki N, Muyodi J, Mwituria J, et al. (2005) Increasing prevalence of multidrug-resistant non-typhoidal salmonellae, Kenya, 1994–2003. *Int J Antimicrob Agents* 25: 38–43.
- Swain MT, Tsai IJ, Assefa SA, Newbold C, Berriman M, et al. (2012) A post-assembly genome-improvement toolkit (PAGIT) to obtain annotated genomes from contigs. *Nat Protoc* 7: 1260–1284.
- Assefa S, Keane TM, Otto TD, Newbold C, Berriman M (2009) ABACAS: algorithm-based automatic contiguation of assembled sequences. *Bioinformatics* 25: 1968–1969.
- Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, et al. (2000) Artemis: sequence visualization and annotation. *Bioinformatics* 16: 944–945.
- Carver T, Berriman M, Tivey A, Patel C, Bohme U, et al. (2008) Artemis and ACT: viewing, annotating and comparing sequences stored in a relational database. *Bioinformatics* 24: 2672–2676.
- Zerbino DR, Birney E (2008) Velvet: algorithms for de novo short read assembly using de Bruijn graphs. *Genome Res* 18: 821–829.
- Boetzer M, Henkel CV, Jansen HJ, Butler D, Pirovano W (2011) Scaffolding pre-assembled contigs using SSPACE. *Bioinformatics* 27: 578–579.
- Boetzer M, Pirovano W (2012) Toward almost closed genomes with GapFiller. *Genome Biol* 13: R56.
- Carver TJ, Rutherford KM, Berriman M, Rajandream MA, Barrell BG, et al. (2005) ACT: the Artemis Comparison Tool. *Bioinformatics* 21: 3422–3423.
- Gouy M, Guindon S, Gascuel O (2010) SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. *Mol Biol Evol* 27: 221–224.
- Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, et al. (2010) New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst Biol* 59: 307–321.
- Rambaut A, Drummond A (2009) FigTree v1. 3.1. Computer program and documentation distributed by the author at <http://tree.bio.ed.ac.uk/software>.
- Harris SR, Feil EJ, Holden MT, Quail MA, Nickerson EK, et al. (2010) Evolution of MRSA during hospital transmission and intercontinental spread. *Science* 327: 469–474.
- Croucher NJ, Harris SR, Fraser C, Quail MA, Burton J, et al. (2011) Rapid pneumococcal evolution in response to clinical interventions. *Science* 331: 430–434.
- Farris JS (1970) Methods for Computing Wagner Trees. *Systematic Zoology* 19: 83–92.
- Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25: 2078–2079.
- Okoro CK, Kingsley RA, Connor TR, Harris SR, Parry CM, et al. (2012) Intracontinental spread of human invasive *Salmonella* Typhimurium pathovariants in sub-Saharan Africa. *Nat Genet* 44: 1215–1221.
- Baumler AJ, Tsois RM, Bowe FA, Kusters JG, Hoffmann S, et al. (1996) The pef fimbrial operon of *Salmonella typhimurium* mediates adhesion to murine small intestine and is necessary for fluid accumulation in the infant mouse. *Infect Immun* 64: 61–68.
- Heffernan EJ, Harwood J, Fierer J, Guiney D (1992) The *Salmonella typhimurium* virulence plasmid complement resistance gene rck is homologous to a family of virulence-related outer membrane protein genes, including pagC and ail. *J Bacteriol* 174: 84–91.
- Frost LS, Ippen-Ihler K, Skurray RA (1994) Analysis of the sequence and gene products of the transfer region of the F sex factor. *Microbiol Rev* 58: 162–210.
- Vandenbosch JL, Kurlandsky DR, Urdangaray R, Jones GW (1989) Evidence of coordinate regulation of virulence in *Salmonella typhimurium* involving the rsk element of the 95-kilobase plasmid. *Infect Immun* 57: 2566–2568.
- Ezquerria E, Burnens AP, Frith K, Costas M, Stanley J (1993) Molecular genotype analysis of *Salmonella bovisorbificans*. *Mol Cell Probes* 7: 45–54.
- Parkhill J, Dougan G, James KD, Thomson NR, Pickard D, et al. (2001) Complete genome sequence of a multiple drug resistant *Salmonella enterica* serovar Typhi CT18. *Nature* 413: 848–852.
- Liu WQ, Liu GR, Li JQ, Xu GM, Qi D, et al. (2007) Diverse genome structures of *Salmonella* paratyphi C. *BMC Genomics* 8: 290.
- Morris C, Tam CK, Wallis TS, Jones PW, Hackett J (2003) *Salmonella enterica* serovar Dublin strains which are Vi antigen-positive use type IVB pili for bacterial self-association and human intestinal cell entry. *Microbial pathogenesis* 35: 279–284.
- McClelland M, Florea L, Sanderson K, Clifton SW, Parkhill J, et al. (2000) Comparison of the *Escherichia coli* K-12 genome with sampled genomes of a *Klebsiella pneumoniae* and three *Salmonella enterica* serovars, Typhimurium, Typhi and Paratyphi. *Nucleic Acids Res* 28: 4974–4986.
- Thomson NR, Clayton DJ, Windhorst D, Vernikos G, Davidson S, et al. (2008) Comparative genome analysis of *Salmonella enteritidis* PT4 and *Salmonella Gallinarum* 287/91 provides insights into evolutionary and host adaptation pathways. *Genome Res* 18: 1624–1637.
- Chiu CH, Tang P, Chu C, Hu S, Bao Q, et al. (2005) The genome sequence of *Salmonella enterica* serovar Choleraesuis, a highly invasive and resistant zoonotic pathogen. *Nucleic Acids Res* 33: 1690–1698.
- Blondel CJ, Jimenez JC, Contreras I, Santiviago CA (2009) Comparative genomic analysis uncovers 3 novel loci encoding type six secretion systems differentially distributed in *Salmonella* serotypes. *BMC Genomics* 10: 354.

54. Shah DH, Lee MJ, Park JH, Lee JH, Eo SK, et al. (2005) Identification of *Salmonella gallinarum* virulence genes in a chicken infection model using? PCR-based signature-tagged mutagenesis. *Microbiology* 151: 3957–3968.
55. Brussow H, Canchaya C, Hardt WD (2004) Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. *Microbiol Mol Biol Rev* 68: 560–602, table of contents.
56. Thomson N, Baker S, Pickard D, Fookes M, Anjum M, et al. (2004) The role of prophage-like elements in the diversity of *Salmonella enterica* serovars. *J Mol Biol* 339: 279–300.
57. Wang X, Kim Y, Ma Q, Hong SH, Pokusaeva K, et al. (2010) Cryptic prophages help bacteria cope with adverse environments. *Nature communications* 1: 147.
58. Ammendola S, Ajello M, Pasquali P, Kroll JS, Langford PR, et al. (2005) Differential contribution of *sodC1* and *sodC2* to intracellular survival and pathogenicity of *Salmonella enterica* serovar *Choleraesuis*. *Microbes Infect* 7: 698–707.
59. Figueroa-Bossi N, Uzzau S, Maloriol D, Bossi L (2001) Variable assortment of prophages provides a transferable repertoire of pathogenic determinants in *Salmonella*. *Mol Microbiol* 39: 260–271.
60. Beuzon CR, Salcedo SP, Holden DW (2002) Growth and killing of a *Salmonella enterica* serovar *Typhimurium* *sifA* mutant strain in the cytosol of different host cell lines. *Microbiology* 148: 2705–2715.
61. Ibarra JA, Steele-Mortimer O (2009) *Salmonella*—the ultimate insider. *Salmonella* virulence factors that modulate intracellular survival. *Cell Microbiol* 11: 1579–1586.
62. Gordon MA, Graham SM, Walsh AL, Wilson L, Phiri A, et al. (2008) Epidemics of invasive *Salmonella enterica* serovar *enteritidis* and *S. enterica* Serovar *typhimurium* infection associated with multidrug resistance among adults and children in Malawi. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 46: 963–969.
63. Mather AE, Reid SW, Maskell DJ, Parkhill J, Fookes MC, et al. (2013) Distinguishable Epidemics of Multidrug-Resistant *Salmonella* *Typhimurium* DT104 in Different Hosts. *Science* 341: 1514–1517.
64. Wehrli W (1983) Rifampin: mechanisms of action and resistance. *Reviews of infectious diseases* 5 Suppl 3: S407–411.
65. Floss HG, Yu TW (2005) Rifamycin-mode of action, resistance, and biosynthesis. *Chemical reviews* 105: 621–632.
66. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, et al. (2001) Structural mechanism for rifampicin inhibition of bacterial rna polymerase. *Cell* 104: 901–912.
67. Bedell RA, Anderson ST, van Lettow M, Akesson A, Corbett EL, et al. (2012) High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. *PLoS One* 7: e39347.
68. Gordon MA, Banda HT, Gondwe M, Gordon SB, Boeree MJ, et al. (2002) Nontyphoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. *AIDS* 16: 1633–1641.
69. Sullivan MJ, Petty NK, Beatson SA (2011) Easyfig: a genome comparison visualizer. *Bioinformatics* 27: 1009–1010.
70. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007) Clustal W and Clustal X version 2.0. *Bioinformatics* 23: 2947–2948.
71. Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, et al. (2010) A new bioinformatics analysis tools framework at EMBL-EBL. *Nucleic Acids Res* 38: W695–699.
72. McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, et al. (2001) Complete genome sequence of *Salmonella enterica* serovar *Typhimurium* LT2. *Nature* 413: 852–856.